Department of Neurosurgery, First Medical Center, Chinese PLA General Hospital, Beijing, China; Institute of Brain Trauma and Neurology, Pingjin Hospital, Characteristic Medical Center of Chinese People's Armed Police Force, Tianjin, China.
Department of Neurosurgery, First Medical Center, Chinese PLA General Hospital, Beijing, China.
Acad Radiol. 2021 Jul;28(7):e189-e198. doi: 10.1016/j.acra.2020.03.008. Epub 2020 Apr 28.
The classification of patients based on pathology and molecular features is important for improving WHO grade II glioma patient prognosis, especially for the initially diagnosed patients. Less invasive and more convenient methods for the prediction of the pathological type and gene status are desired.
This study investigates the ability to use conventional magnetic resonance imaging (MRI) and computed tomography (CT) features for determining the Isocitrate Dehydrogenase (IDH)-mutant and 1p/19q-codeletion status, through a retrospective review of information obtained from 189 WHO grade II glioma patients. Diffuse astrocytoma (IDH-mutant), Diffuse astrocytoma (IDH- wildtype) and Oligodendroglioma (IDH-mutant and 1p/19q co-deletion) were included in this cohort. All patients were divided into IDH-mutant group and IDH-wildtype group according to the IDH R132H mutation status. Moreover, all patients were divided into 1p/19q co-deletion group and 1p/19q non-codeletion group according to the 1p and 19q chromosome status. Patients underwent pre-operative CT and MRI scans, followed by operation and histopathological analyses, including immunohistochemistry and polymerase chain reaction analysis for IDH mutants, and fluorescence capillary electrophoresis analysis for the 1p/19q co-deletion. The χ test, logistical regression and receiver operating characteristic curve analysis were conducted for statistical analysis.
IDH-mutant group patients exhibited a higher calcification frequency (25.2% vs 2.4%, p = 0.006) and lower frequency of T1 enhancement (20.4% vs 38.1%, p = 0.028) comparing patients in IDH-wildtype group, while 1p/19q co-deletion group patients exhibited a higher calcification frequency (46.67% vs 2.6%, p < 0.001) and lower homogenous signal frequency in T2WI (12.0% vs 31.6%, p = 0.014), sharp lesion margins (14.7% vs 43.0%, p = 0.010), T2/fluid attenuated inversion recovery mismatch signs (22.7% vs 50.9%, p = 0.001), and subventricular zone involvement (64.0% vs 15.8%, p = 0.021) comparing patients in 1p/19q non-codeletion group. According to the results of receiver operating characteristic analysis, these features were observed to have certain diagnostic abilities, especially with regard to combination parameters, which had a high diagnostic capability, with an area under the curve of 0.848.
Conventional MRI and CT features, which still represent the most convenient and widely used predictive method, might be a promising noninvasive predictor for differentiating between varied WHO grade II gliomas. Patients with calcification and T1 nonenhancement are more likely to be IDH-mutant. Moreover, patients with noncalcification, homogenous signal, sharp lesion margins, subventricular zone involvement on T2 and T2/fluid attenuated inversion recovery mismatch signs are more likely to be 1p/19q non-codeletion.
基于病理和分子特征对患者进行分类,对于提高 WHO 二级胶质瘤患者的预后具有重要意义,特别是对于初诊患者。目前希望有一些更微创、更便捷的方法来预测病理类型和基因状态。
本研究通过回顾性分析 189 例 WHO 二级胶质瘤患者的信息,探讨使用常规磁共振成像(MRI)和计算机断层扫描(CT)特征来确定异柠檬酸脱氢酶(IDH)突变状态和 1p/19q 缺失状态的能力。本研究纳入弥漫性星形细胞瘤(IDH 突变型)、弥漫性星形细胞瘤(IDH 野生型)和少突胶质细胞瘤(IDH 突变型和 1p/19q 共缺失型)。所有患者均根据 IDH R132H 突变状态分为 IDH 突变组和 IDH 野生型组。此外,所有患者均根据 1p 和 19q 染色体状态分为 1p/19q 共缺失组和 1p/19q 非缺失组。患者行术前 CT 和 MRI 扫描,然后行手术和组织病理学分析,包括 IDH 突变的免疫组化和聚合酶链反应分析,以及 1p/19q 共缺失的荧光毛细管电泳分析。采用 χ 检验、逻辑回归和受试者工作特征曲线分析进行统计学分析。
与 IDH 野生型组相比,IDH 突变组患者的钙化频率更高(25.2% vs 2.4%,p=0.006),T1 增强频率更低(20.4% vs 38.1%,p=0.028),而 1p/19q 共缺失组患者的钙化频率更高(46.67% vs 2.6%,p<0.001),T2WI 信号均匀性更低(12.0% vs 31.6%,p=0.014),病灶边界更锐利(14.7% vs 43.0%,p=0.010),T2/液体衰减反转恢复失匹配征更多见(22.7% vs 50.9%,p=0.001),室周带侵犯更常见(64.0% vs 15.8%,p=0.021)。根据受试者工作特征分析结果,这些特征具有一定的诊断能力,特别是组合参数具有较高的诊断能力,曲线下面积为 0.848。
尽管常规 MRI 和 CT 特征仍是最便捷、应用最广泛的预测方法,但它们可能是一种有前途的非侵入性预测方法,有助于区分不同的 WHO 二级胶质瘤。具有钙化和 T1 非增强特征的患者更有可能为 IDH 突变型。此外,无钙化、信号均匀、病灶边界锐利、T2 和 T2/液体衰减反转恢复失匹配征存在室周带侵犯的患者更有可能为 1p/19q 非缺失型。